Benchmark Study Sample Clauses

Benchmark Study. Upon request by the Owner, the Manager shall promptly prepare and deliver to the Owner a report containing corrective and deferred maintenance work or capital improvements required to be performed at the Property.
Sample 1Sample 2
AutoNDA by SimpleDocs
Benchmark Study a) At the end of the first * * * years of the Term and at the end of each * * * year period thereafter, Equifax U.S. may elect to have a benchmark study performed for all in-scope Towers on a Transaction Document basis or for any subset of such Towers. The cost payable to a third party benchmark organization for the benchmark activity will be split equally by the Parties. The Parties will jointly designate and engage the third party benchmark organization. The benchmark study will focus on outsourcing services providers that regularly provide the full range of Services provided by IBM to the Equifax Group under the Agreement and on the outsourcing engagements of those providers for substantially similar services in substantially similar quantities. b) Each Transaction Document will set forth a price/performance value for each Tower included in Services provided under such Transaction Document and the scale or system against which such price/performance value was determined (the "Performance Value"). The Performance Value will be either the Norm or an agreed deviation from the Norm, and the Parties shall exercise the rights and obligations described herein if IBM's overall performance rating with respect to the Services is not as good as the agreed upon Performance Value. For purposes of the Agreement, the "NORM" shall be the average price/performance of all customers (both outsourced and non-outsourced customers) being compared during the benchmark study against the scale or system pursuant to which such customers were measured. c) The result of each benchmark study will be submitted to the IPT, Equifax and IBM. In the event that the benchmark study indicates that IBM's overall performance rating as compared to the applicable Performance Value rating for any Tower under a Transaction Document is not as good as the Performance Value for such Tower(s), the IPT will promptly use such study as an evaluative tool to identify opportunities for improvements in the technical configuration, performance, cost and/or aggregate pricing of the Services allocable to such Tower(s). d) With respect to each area identified by the IPT in each benchmark study as an area for improvement in the * * * Indicates omitted material that is the subject of a Confidential Treatment Request filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933. Equifax / IBM Confidential technical configuration, performance, cost and/or aggregat...
Sample 1
Benchmark Study. Upon the commencement of the Initial Term, Manager shall perform a walk-through of each Property and shall note corrective and deferred maintenance work or capital improvements required to be performed. Promptly after the completion of such walk-through, Manager shall prepare and deliver to the Owner a report containing the results of that study.
Sample 1
Benchmark Study. 37 9.9 Service Credits................................................................................38 9.10
Sample 1
Benchmark Study. (a) The Contracting Authority must commission a Benchmark Study no later than 6 months prior to a Market Review Date. (b) The Benchmark Study will include a comparison of the costs of one or more Relevant Services to be specified by the Contracting Authority with the costs of comparable services in the market place. (c) The Benchmark Study must be carried out by an independent expert appointed by one of the Parties. The costs associated with the Benchmark Study will be borne by the Contracting Authority. (d) The Contracting Authority and the independent expert shall be entitled for purposes of the Benchmark Study to examine the Contractor’s costs and the costs of the Contractor’s Subcontractors and suppliers in regard to the Relevant Service and relevant ancillary costs. (e) All confidential business information shall be treated as such by the Contracting Authority and the independent expert. To this end, the Contracting Authority shall arrange for the independent expert to sign a nondisclosure agreement whose terms will have already been agreed to by the Contractor prior to the appointment of the independent expert. (f) The independent expert shall compare the costs per Payment Period in respect of a service that is comparable with each designated Relevant Service available on the market with the Contractor’s costs for the Relevant Service, as outlined in the subcontracting agreement(s) upon signature of the Agreement, and revised in accordance with: (i) the applicable indexation; (ii) Contracting Authority Changes if any; and (iii) changes in legislation and regulations, if applicable; these being the Corrected Original Costs. (g) The Contractor and the Contracting Authority are obliged to discuss the outcome of the Benchmark Study. (h) The Benchmark Study must be completed within 2 months and the ensuing discussion between the Parties must be completed within 1 month. (i) If the Contracting Authority and the Contractor jointly conclude with regard to the discussion referred to in Paragraph (g) that the Benchmark Study shows that the costs of a similar service in the market compared with the Relevant Service are lower than 95% of the Corrected Original Costs for the said Relevant Service, the Contractor shall pay the Contracting Authority as and from the Market Review Date to the next Market Review Date a sum per Payment Period equal to 50% of the difference between the Corrected Original Costs and the said market costs. (j) If the discussion referred to...
Sample 1
Benchmark Study. In 2014, MULU Worksite conducted a cross-sectional benchmark survey with worksite employees at 18 randomly selected worksites to assess HIV prevalence and risk behaviors among the worksite population. Employees were interviewed in three types of worksites: highly mobile mega-sites, semi-mobile large-scale sites, and less mobile stable worksites. A two-stage stratified sampling design was implemented, selecting worksites in the first stage and employees in the second stage. The primary sampling units were large-scale worksites (with populations 500 workers or more). A total of 1,285 interviews and 1,261 HIV tests with response rate of 95.2% and 98.1% of interview participants respectively were completed. The study population was predominantly male (86.8%), and two-thirds were below the age of 30. Key findings include: The HIV prevalence in the worksite population was found to be 2.1%, higher than 1.2% projected adult prevalence in the general population in Ethiopia from 2014. HIV prevalence varied across different segments of the worksite population and was higher among workers whose age was greater than 40 years (5.2%), those who were divorced or separated (10.5%). Among the study population, HIV prevalence was higher (7.5%) among those who had paid sex in the last three months than those who had not had paid sex (1.8%), p<0.05. Likewise, HIV prevalence was higher among those who had had sex with a casual partner in the last three months than those who didn't (p<0.001). The frequency of using drugs/khat also had a significant association with HIV prevalence (p<0.001). HIV prevalence was 17.6% among those who consumed drugs/khat every day, 6.3% among those who consumed drugs/khat a couple of times per week, 8.9% among those who used less than once per week, and 1.5% among those who never used drugs/khat. Those who had never been tested for HIV were more likely to test positive for HIV (p<0.05). The HIV prevalence among who had never been tested for HIV was 5.2% versus 2.0% among those who had been tested. The majority of the study population (73.2%) had engaged in sex. Of those who had sex, 30.2% had sex with a non-marital regular sexual partner in the last three months, 5.5% had sex with a casual partner and 5.2% had sex with a paid partner. Condom use at last sex with a paid sexual partner was 81.6%, compared to 57.7% with a casual partner and 7.9% with non-marital regular partner. The main reported reason for not using condoms with a non-marital regular ...
Sample 1

Related to Benchmark Study

  • Commercialization Plan (a) Not later than three [***] after submission of Regulatory Filings for each Product in each country of the Territory, Licensee will provide to the JCC for review its initial Commercialization Plan for each Product for each country in the Territory. Such initial Commercialization Plan will describe Licensee’s plans for activities to be conducted for such Product for such country. Each Commercialization Plan shall include the details of obligations to be performed by Licensee to achieve the specific activities that are applicable to the stage of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization (e.g., pre-launch, launch planning, launch, or post-launch) of the applicable Product during the time period covered by such Commercialization Plan and subsequent time periods. (b) Prior to the First Commercial Sale for such Product in such country, Licensee will provide to the JCC for review an updated Commercialization Plan for such Product for such country. Such updated Commercialization Plan will include, but not be limited to, Licensee’s updated plans for activities to be conducted for such Product for such country prior to launch as well as activities to be conducted in connection with such launch. (c) Promptly after each anniversary of the First Commercial Sale of such Product during the Term, Licensee will provide to the JCC for review updated Commercialization Plans for such Product for such country. Such further updated Commercialization Plan will include, but not be limited to, Licensee’s plans for Commercialization activities for such Product and such country for the twelve (12) month period following the date of delivery of such Commercialization Plan. No Commercialization Plan may be implemented by Licensee if [***]. Each Commercialization Plan shall be consistent with and shall not contradict the terms of this Agreement [***], and in the event of any inconsistency between the Commercialization Plan and this Agreement, the terms of this Agreement shall prevail. Notwithstanding the foregoing, if a [***], Licensee shall [***] and shall promptly [***].

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular: (a) review and recommend the Commercialization Plans and related activities with respect to the Commercialization of Products in the Collaborator Territory, and report to the JEC on all significant Commercialization activities in the Collaborator Territory; (b) provide a forum for and facilitate communications and coordination between the Parties with respect to the Commercialization of Products in the Collaborator Territory and the Exelixis Territory; (c) on an annual basis, discuss and establish Collaborator’s Minimum Commercial Performance thresholds pursuant to Section 6.3(b) and propose recommendation to JEC; [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. (d) review the status of material Product manufacturing and supply activities and strategies associated with Commercialization; (e) review and discuss the major findings of Collaborator’s market research with respect to any Product in the Collaborator Territory, if any; (f) review and oversee the branding and product positioning strategy for Products in the Collaborator Territory and evaluate Collaborator’s brand strategy for the Product in the Collaborator Territory for consistency with the then-current global brand strategy for the Product; (g) discuss Product list price and status of reimbursement in the Collaborator Territory; and (h) perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Commercialization of Products, including endeavoring to resolve any disputes between the Parties arising from the deliberations of the JCC, or as otherwise directed by the JEC.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Benchmarks 2.1 Benchmarks set forth the overall scope and level of responsibility and the typical duties by which jobs or positions are distinguished and classified under the Classification System. 2.2 Benchmarks also set forth the range or level of qualifications appropriate for a position classified to the level of the benchmark(s). 2.3 Benchmarks do not describe jobs or positions. They are used to classify a wide diversity of jobs by identifying the scope and level of responsibilities.

  • Benchmarking 19.1 The Parties shall comply with the provisions of Framework Schedule 12 (Continuous Improvement and Benchmarking) in relation to the benchmarking of any or all of the Goods and/or Services.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!